Should I buy or sell Crinetics Pharmaceuticals stock right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Crinetics Pharmaceuticals in the last twelve months. There are currently 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CRNX shares. View CRNX analyst ratings or view top-rated stocks .

What is Crinetics Pharmaceuticals' stock price target for 2024?

9 equities research analysts have issued 12 month price objectives for Crinetics Pharmaceuticals' stock. Their CRNX share price targets range from $33.00 to $56.00. On average, they anticipate the company's stock price to reach $44.38 in the next year. This suggests a possible upside of 34.7% from the stock's current price. View analysts price targets for CRNX or view top-rated stocks among Wall Street analysts .

How have CRNX shares performed in 2023?

Crinetics Pharmaceuticals' stock was trading at $18.30 at the start of the year. Since then, CRNX stock has increased by 80.1% and is now trading at $32.95. View the best growth stocks for 2023 here .

Are investors shorting Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals saw a drop in short interest in November. As of November 15th, there was short interest totaling 6,200,000 shares, a drop of 7.6% from the October 31st total of 6,710,000 shares. Based on an average daily trading volume, of 1,550,000 shares, the days-to-cover ratio is currently 4.0 days. View Crinetics Pharmaceuticals' Short Interest .

When is Crinetics Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024. View our CRNX earnings forecast .

How were Crinetics Pharmaceuticals' earnings last quarter?

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) released its quarterly earnings data on Tuesday, November, 7th. The company reported ($1.01) EPS for the quarter, missing the consensus estimate of ($0.89) by $0.12. The firm had revenue of $0.35 million for the quarter. Crinetics Pharmaceuticals had a negative trailing twelve-month return on equity of 57.04% and a negative net margin of 4,223.27%.

What ETF holds Crinetics Pharmaceuticals' stock ?

iShares Micro-Cap ETF holds 121,735 shares of CRNX stock, representing 0.25% of its portfolio.

What is R. Scott Struthers, Ph.D.'s approval rating as Crinetics Pharmaceuticals' CEO?

6 employees have rated Crinetics Pharmaceuticals Chief Executive Officer R. Scott Struthers, Ph.D. on Glassdoor.com . R. Scott Struthers, Ph.D. has an approval rating of 100% among the company's employees. This puts R. Scott Struthers, Ph.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 68.0% of employees surveyed would recommend working at Crinetics Pharmaceuticals to a friend.

What other stocks do shareholders of Crinetics Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Crinetics Pharmaceuticals investors own include SCYNEXIS (SCYX) , Sorrento Therapeutics (SRNE) , Aldeyra Therapeutics (ALDX) , G1 Therapeutics (GTHX) , Kura Oncology (KURA) , Otonomy (OTIC) , Selecta Biosciences (SELB) , TG Therapeutics (TGTX) , Arbutus Biopharma (ABUS) and Applied Genetic Technologies (AGTC) .

When did Crinetics Pharmaceuticals IPO?

(CRNX) raised $80 million in an initial public offering on Wednesday, July 18th 2018. The company issued 5,000,000 shares at $15.00-$17.00 per share. J.P. Morgan, Leerink Partners and Piper Jaffray served as the underwriters for the IPO.

Who are Crinetics Pharmaceuticals' major shareholders?

Crinetics Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Wellington Management Group LLP (5.45%), FMR LLC (3.20%), Jennison Associates LLC (2.62%), Eventide Asset Management LLC (1.53%), Avidity Partners Management LP (0.91%) and Northern Trust Corp (0.89%). Insiders that own company stock include Ajay Madan , Alan Seth Krasner, Coelho Rogerio Vivaldi, Dana Pizzuti, Jeff E Knight, Marc Wilson, Matthew K Fust , Perceptive Advisors Llc, Richard Scott Struthers and Stephen F Betz . View institutional ownership trends .

How do I buy shares of Crinetics Pharmaceuticals?

Shares of CRNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Crinetics Pharmaceuticals Stock Price, News & Analysis (NASDAQ:CRNX)

$33.50

+0.27 (+0.81%)

(As of 02:09 PM ET)

Compare

Today's Range: $32.82
▼
$33.65
50-Day Range: $25.62
▼
$33.50
52-Week Range: $15.23
▼
$34.09

Volume: 193,054 shs
Average Volume: 769,292 shs
Market Capitalization: $2.24 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $44.38

Crinetics Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 34.7% Upside
$44.38 Price Target
Short Interest: Healthy
9.28% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.62
Upright™ Environmental Score
News Sentiment: 0.32
Based on 6 Articles This Week
Insider Trading: Selling Shares
$6.68 M Sold Last Quarter
Proj. Earnings Growth: Growing
From ($3.66) to ($3.46) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.63 out of 5 stars

Medical Sector

119th out of 958 stocks

Pharmaceutical Preparations Industry

29th out of 396 stocks

4.5

Analyst's Opinion

Consensus Rating
Crinetics Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $44.38, Crinetics Pharmaceuticals has a forecasted upside of 34.7% from its current price of $32.95.
Amount of Analyst Coverage
Crinetics Pharmaceuticals has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.0

Short Interest

Percentage of Shares Shorted
9.28% of the outstanding shares of Crinetics Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
Crinetics Pharmaceuticals has a short interest ratio ("days to cover") of 4.
Change versus previous month
Short interest in Crinetics Pharmaceuticals has recently decreased by 7.60%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Crinetics Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Crinetics Pharmaceuticals does not have a long track record of dividend growth.

3.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Crinetics Pharmaceuticals has received a 46.37% net impact score from Upright. Crinetics Pharmaceuticals seems to create the most significant positive value in categories "Jobs", "Creating knowledge", and "Physical diseases". The positive contribution in the "Creating knowledge" impact category is false driven by its "Clinical research services for physical health", "Basic medical research services", and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Crinetics Pharmaceuticals is -0.62.

2.4

News and Social Media Coverage

News Sentiment
Crinetics Pharmaceuticals has a news sentiment score of 0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.50 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 6 news articles for Crinetics Pharmaceuticals this week, compared to 2 articles on an average week.
Search Interest
7 people have searched for CRNX on MarketBeat in the last 30 days. This is an increase of 40% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Crinetics Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Crinetics Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,676,966.00 in company stock.
Percentage Held by Insiders
Only 7.00% of the stock of Crinetics Pharmaceuticals is held by insiders.
Percentage Held by Institutions
98.51% of the stock of Crinetics Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Crinetics Pharmaceuticals are expected to grow in the coming year, from ($3.66) to ($3.46) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Crinetics Pharmaceuticals is -9.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Crinetics Pharmaceuticals is -9.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Crinetics Pharmaceuticals has a P/B Ratio of 5.60. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Crinetics Pharmaceuticals Stock (NASDAQ:CRNX)

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for endocrine diseases and endocrine-related tumors. The company's lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). It is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. The company was incorporated in 2008 and is headquartered in San Diego, California.

CRNX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CRNX Stock News Headlines

December 6, 2023 | americanbankingnews.com

Crinetics Pharmaceuticals (NASDAQ:CRNX) Stock Rating Reaffirmed by Cantor Fitzgerald

December 4, 2023 | benzinga.com

Crinetics Pharmaceuticals Stock (NASDAQ:CRNX) Insider Trades

December 7, 2023 | Edge On The Street (Ad)

An Unusual Way to Invest in Gold

Most financial experts recommend including gold in your investment mix to protect against rising prices and keep wealth secure. Investors are discovering a little-known way to benefit from gold, which offers the chance to gain from higher gold prices and mining successes while avoiding the costs of operating mines.

December 4, 2023 | benzinga.com

Crinetics Pharmaceuticals Stock (NASDAQ:CRNX) Dividends: History, Yield and Dates

December 3, 2023 | americanbankingnews.com

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives $44.38 Consensus PT from Brokerages

November 28, 2023 | seekingalpha.com

Crinetics Pharmaceuticals: Some Caution Warranted

November 20, 2023 | finance.yahoo.com

Crinetics Pharmaceuticals to Participate in Upcoming Investor Conferences

November 20, 2023 | finance.yahoo.com

Crinetics Pharmaceuticals to Participate in Upcoming Investor Conferences

December 7, 2023 | Edge On The Street (Ad)

An Unusual Way to Invest in Gold

November 20, 2023 | markets.businessinsider.com

8 Analysts Have This to Say About Crinetics Pharmaceuticals

November 17, 2023 | finance.yahoo.com

Billionaire Steve Cohen Goes Big on These 2 ‘Strong Buy’ Stocks — Here’s Why You Should Follow

November 11, 2023 | finanznachrichten.de

Crinetics Pharmaceuticals, Inc.: Crinetics Pharmaceuticals Announces November 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 10, 2023 | finance.yahoo.com

Crinetics Pharmaceuticals Announces November 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 10, 2023 | markets.businessinsider.com

Positive Outlook on Crinetics Pharmaceuticals: Leland Gershell’s Analysis of Clinical Programs and Financial Stability

November 9, 2023 | finance.yahoo.com

Crinetics Pharmaceuticals Inc (CRNX) Reports Q3 2023 Results: Phase 3 Success and Financial Growth

November 8, 2023 | markets.businessinsider.com

Buy Rating for Crinetics Pharmaceuticals: Promising Future with Upcoming Phase 3 PATHFNDR-2 Data and Strong Financial Position

November 8, 2023 | finance.yahoo.com

Here's What Could Help Crinetics Pharmaceuticals, Inc. (CRNX) Maintain Its Recent Price Strength

November 8, 2023 | finance.yahoo.com

Wall Street Analysts See a 56.94% Upside in Crinetics Pharmaceuticals, Inc. (CRNX): Can the Stock Really Move This High?

November 7, 2023 | finance.yahoo.com

Crinetics Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update

November 4, 2023 | finance.yahoo.com

Insider Sell: CFO Marc Wilson Sells 10,000 Shares of Crinetics Pharmaceuticals Inc (CRNX)

October 26, 2023 | markets.businessinsider.com

Oppenheimer Reaffirms Their Buy Rating on Crinetics Pharmaceuticals (CRNX)

October 24, 2023 | markets.businessinsider.com

11 Analysts Have This to Say About Crinetics Pharmaceuticals

October 23, 2023 | finance.yahoo.com

What Makes Crinetics Pharmaceuticals, Inc. (CRNX) a Good Fit for 'Trend Investing'

October 23, 2023 | finance.yahoo.com

Wall Street Analysts Think Crinetics Pharmaceuticals, Inc. (CRNX) Could Surge 55.53%: Read This Before Placing a Bet

October 20, 2023 | finance.yahoo.com

Insider Sell: Chief Medical Officer Alan Krasner Sells 7,000 Shares of Crinetics Pharmaceuticals Inc

October 6, 2023 | finance.yahoo.com

Swelling losses haven't held back gains for Crinetics Pharmaceuticals (NASDAQ:CRNX) shareholders since they're up 58% over 3 years

October 5, 2023 | msn.com

Crinetics Pharmaceuticals (CRNX) Price Target Increased by 7.25% to 49.47

See More Headlines

Receive CRNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Crinetics Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/07/2023
Today: 12/07/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 2/27/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:CRNX
CUSIP: N/A
CIK: 1658247
Web: www.crinetics.com
Phone: (858) 450-6464
Fax: N/A
Employees: 210
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $44.38
High Stock Price Target: $56.00
Low Stock Price Target: $33.00
Potential Upside/Downside: +33.5%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 9 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.64)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-163,920,000.00
Net Margins: -4,223.27%
Pretax Margin: -4,202.16%
Return on Equity: -57.04%
Return on Assets: -49.83%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 14.23
Quick Ratio: 14.23

Sales & Book Value

Annual Sales: $4.74 million
Price / Sales: 468.30
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $5.88 per share
Price / Book: 5.65

Miscellaneous

Outstanding Shares: 66,800,000
Free Float: 62,123,000
Market Cap: $2.22 billion
Optionable: Not Optionable
Beta: 0.55

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

Dr. R. Scott Struthers Ph.D. (Age 61)
Founder, President, CEO & Director
Comp: $870.69k
Dr. Stephen F. Betz Ph.D. (Age 57)
Founder & Chief Scientific Officer
Comp: $618.58k
Mr. Marc J. C. Wilson (Age 44)
Chief Financial Officer
Comp: $585.54k
Mr. James Hassard (Age 57)
Chief Commercial Officer
Comp: $513.34k
Dr. Dana Pizzuti M.D. (Age 67)
Chief Development Officer
Comp: $493.62k
Mr. Jeff E. Knight (Age 52)
Chief Operating Officer
Comp: $237.64k
Ms. Garlan Adams
General Counsel & Corporate Secretary
Ms. Adriana Cabre M.B.A.
Chief Human Resources Officer
Dr. Alan S. Krasner M.D. (Age 60)
Chief Medical Officer
Comp: $571.97k
Mr. Kevin Capps
Head of Intellectual Property

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CRNX Stock Analysis - Frequently Asked Questions

Should I buy or sell Crinetics Pharmaceuticals stock right now?: 9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Crinetics Pharmaceuticals in the last twelve months. There are currently 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CRNX shares.
View CRNX analyst ratings or view top-rated stocks.
What is Crinetics Pharmaceuticals' stock price target for 2024?: 9 equities research analysts have issued 12 month price objectives for Crinetics Pharmaceuticals' stock. Their CRNX share price targets range from $33.00 to $56.00. On average, they anticipate the company's stock price to reach $44.38 in the next year. This suggests a possible upside of 34.7% from the stock's current price.
View analysts price targets for CRNX or view top-rated stocks among Wall Street analysts.
How have CRNX shares performed in 2023?: Crinetics Pharmaceuticals' stock was trading at $18.30 at the start of the year. Since then, CRNX stock has increased by 80.1% and is now trading at $32.95.
View the best growth stocks for 2023 here.
Are investors shorting Crinetics Pharmaceuticals?: Crinetics Pharmaceuticals saw a drop in short interest in November. As of November 15th, there was short interest totaling 6,200,000 shares, a drop of 7.6% from the October 31st total of 6,710,000 shares. Based on an average daily trading volume, of 1,550,000 shares, the days-to-cover ratio is currently 4.0 days.
View Crinetics Pharmaceuticals' Short Interest.
When is Crinetics Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024.
View our CRNX earnings forecast.
How were Crinetics Pharmaceuticals' earnings last quarter?: Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) released its quarterly earnings data on Tuesday, November, 7th. The company reported ($1.01) EPS for the quarter, missing the consensus estimate of ($0.89) by $0.12. The firm had revenue of $0.35 million for the quarter. Crinetics Pharmaceuticals had a negative trailing twelve-month return on equity of 57.04% and a negative net margin of 4,223.27%.

What ETF holds Crinetics Pharmaceuticals' stock ?: iShares Micro-Cap ETF holds 121,735 shares of CRNX stock, representing 0.25% of its portfolio.
What is R. Scott Struthers, Ph.D.'s approval rating as Crinetics Pharmaceuticals' CEO?: 6 employees have rated Crinetics Pharmaceuticals Chief Executive Officer R. Scott Struthers, Ph.D. on Glassdoor.com. R. Scott Struthers, Ph.D. has an approval rating of 100% among the company's employees. This puts R. Scott Struthers, Ph.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 68.0% of employees surveyed would recommend working at Crinetics Pharmaceuticals to a friend.
What other stocks do shareholders of Crinetics Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Crinetics Pharmaceuticals investors own include SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), G1 Therapeutics (GTHX), Kura Oncology (KURA), Otonomy (OTIC), Selecta Biosciences (SELB), TG Therapeutics (TGTX), Arbutus Biopharma (ABUS) and Applied Genetic Technologies (AGTC).
When did Crinetics Pharmaceuticals IPO?: (CRNX) raised $80 million in an initial public offering on Wednesday, July 18th 2018. The company issued 5,000,000 shares at $15.00-$17.00 per share. J.P. Morgan, Leerink Partners and Piper Jaffray served as the underwriters for the IPO.
Who are Crinetics Pharmaceuticals' major shareholders?: Crinetics Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Wellington Management Group LLP (5.45%), FMR LLC (3.20%), Jennison Associates LLC (2.62%), Eventide Asset Management LLC (1.53%), Avidity Partners Management LP (0.91%) and Northern Trust Corp (0.89%). Insiders that own company stock include Ajay Madan, Alan Seth Krasner, Coelho Rogerio Vivaldi, Dana Pizzuti, Jeff E Knight, Marc Wilson, Matthew K Fust, Perceptive Advisors Llc, Richard Scott Struthers and Stephen F Betz.
View institutional ownership trends.
How do I buy shares of Crinetics Pharmaceuticals?: Shares of CRNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:CRNX) was last updated on 12/7/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial